What is the recovery time after stem cell therapy for Macular Degeneration & Vision?
Recovery and risk depend on the exact product and whether administration is intravitreal, subretinal or otherwise surgical, so a universal timeline is unsafe. Trial documents should describe anaesthesia, positioning if required, activity restrictions, infection, inflammation, retinal-detachment and pressure monitoring, emergency arrangements and follow-up. Visual change should be assessed with protocol-defined measures, not assumed from a standard integration period.
What the evidence shows for Macular Degeneration & Vision
Human retinal cell-therapy studies are early and heterogeneous, involving different diseases, cell products, surgical routes and endpoints. Small-cohort safety observations and exploratory visual changes do not establish durable vision stabilisation or restoration. Imaging, light sensitivity and visual-acuity measures should not be merged into a single response claim. No pooled response rate is published here because the studies are too heterogeneous for a single figure to be meaningful. The registered studies and their own prespecified endpoints are listed in the registry table on this page.
Am I a candidate? → · Macular Degeneration & Vision: full overview → · Macular Degeneration & Vision cost → · Cost →
Evidence checked against ISSCR, FDA and EMA guidance. See our editorial standards. This is information, not medical advice. Educational information, not medical advice; figures indicative.
Sources & further reading
More on this condition
- Macular Degeneration & Vision: cell-therapy evidence and registered trials
- How much does stem cell therapy for Macular Degeneration & Vision cost? (2026)
- Macular Degeneration & Vision stem cell therapy — your questions answered (2026)
- Macular Degeneration & Vision: cell-therapy evidence by therapy class